A Hormel Fellow researcher in the Molecular Therapeutics and Cancer Health Disparity lab of The Hormel Institute, University of Minnesota received an award from the Society for Basic Urological Research 2017 Fall Symposium in recognition of his excellent research.

Dr. Arsheed Ganaie presented his research “A Novel Approach To Treat Neuroendocrine And Metastatic Prostate Cancer: Targeting S100A4 Protein by Small Molecule Inhibitor” at the international symposium and received a check and certificate for his contributions in a Travel Awards presentation.

The symposium was held Nov. 9-12, 2017, at Tampa, Florida.

Prostate cancer is the most prevalent cancer affecting men, besides skin cancer, according to Hormel Institute officials.

An estimated 161,360 new cases of prostate cancer will be diagnosed in 2017 and American men have an approximate one in eight chance of developing prostate cancer during their lifetimes.

The current standard therapy is not sufficient to treat the metastatic and neuroendocrine type of prostate cancer in human patients. About 8 percent of male cancer deaths are caused by prostate cancer, and The Hormel Institute’s Molecular Therapeutics and Cancer Health Disparity lab, led by Dr. M. Saleem Bhat, works to improve those numbers through groundbreaking research.

“We are very pleased Dr. Ganaie was selected to present our lab’s research at the symposium,” said Bhat. “This very promising research will continue to be shared with an important scientific audience as together we continue to look for new and better ways to prevent and control prostate cancer.”